Review



recombinant human trail (dulanermin)  (Genentech inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Genentech inc recombinant human trail (dulanermin)
    Recombinant Human Trail (Dulanermin), supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+trail+dulanermin/apo2l+trail/pmc05738353-158-4-8
    Average 90 stars, based on 1 article reviews
    recombinant human trail (dulanermin) - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    Clinical Proteomics:

    Article Title: Mechanistic Elucidation of the Antitumor Properties of Withaferin A in Breast Cancer
    Article Snippet: .. It is interesting to note that in recent years, many phase I and II single agent and combination clinical trials have been conducted to examine the efficacy and safety of recombinant human TRAIL (dulanermin; Amgen/Genentech), and the agonistic monoclonal antibodies to DR5 [lexatumumab (Human Genome Sciences), conatumumab (Amgen), drozitumab (Genentech), tigatuzumab (Daiichi-Sankyo), and LBY135 (Novartis); refs. 44, 47]. ..

    Article Title: Mechanistic elucidation of the antitumor properties of withaferin A in breast cancer
    Article Snippet: .. It is interesting to note that in recent years, many phase 1 and 2 single agent and combination clinical trials have been conducted to examine the efficacy and safety of recombinant human TRAIL (dulanermin, (Amgen/Genentech)), and the agonistic monoclonal antibodies to DR5 (lexatumumab (Human Genome Sciences), conatumumab (Amgen), drozitumab (Genentech), tigatuzumab (Daiichi-Sankyo) and LBY135 (Novartis)) ( 44 , 47 ). ..

    Recombinant:

    Article Title: Mechanistic Elucidation of the Antitumor Properties of Withaferin A in Breast Cancer
    Article Snippet: .. It is interesting to note that in recent years, many phase I and II single agent and combination clinical trials have been conducted to examine the efficacy and safety of recombinant human TRAIL (dulanermin; Amgen/Genentech), and the agonistic monoclonal antibodies to DR5 [lexatumumab (Human Genome Sciences), conatumumab (Amgen), drozitumab (Genentech), tigatuzumab (Daiichi-Sankyo), and LBY135 (Novartis); refs. 44, 47]. ..

    Article Title: Mechanistic elucidation of the antitumor properties of withaferin A in breast cancer
    Article Snippet: .. It is interesting to note that in recent years, many phase 1 and 2 single agent and combination clinical trials have been conducted to examine the efficacy and safety of recombinant human TRAIL (dulanermin, (Amgen/Genentech)), and the agonistic monoclonal antibodies to DR5 (lexatumumab (Human Genome Sciences), conatumumab (Amgen), drozitumab (Genentech), tigatuzumab (Daiichi-Sankyo) and LBY135 (Novartis)) ( 44 , 47 ). ..

    Article Title: Immunoglobulin Fc Domain Fusion to TRAIL Significantly Prolongs Its Plasma Half-Life and Enhances Its Antitumor Activity
    Article Snippet: .. However, for therapy using recombinant human TRAIL (rhTRAIL or Dulanermin, Genentech/Amgen), one major limitation is the rapid blood clearance of TRAIL in vivo. ..

    Bioprocessing:

    Article Title: Mechanistic Elucidation of the Antitumor Properties of Withaferin A in Breast Cancer
    Article Snippet: .. It is interesting to note that in recent years, many phase I and II single agent and combination clinical trials have been conducted to examine the efficacy and safety of recombinant human TRAIL (dulanermin; Amgen/Genentech), and the agonistic monoclonal antibodies to DR5 [lexatumumab (Human Genome Sciences), conatumumab (Amgen), drozitumab (Genentech), tigatuzumab (Daiichi-Sankyo), and LBY135 (Novartis); refs. 44, 47]. ..

    Article Title: Mechanistic elucidation of the antitumor properties of withaferin A in breast cancer
    Article Snippet: .. It is interesting to note that in recent years, many phase 1 and 2 single agent and combination clinical trials have been conducted to examine the efficacy and safety of recombinant human TRAIL (dulanermin, (Amgen/Genentech)), and the agonistic monoclonal antibodies to DR5 (lexatumumab (Human Genome Sciences), conatumumab (Amgen), drozitumab (Genentech), tigatuzumab (Daiichi-Sankyo) and LBY135 (Novartis)) ( 44 , 47 ). ..

    In Vivo:

    Article Title: Immunoglobulin Fc Domain Fusion to TRAIL Significantly Prolongs Its Plasma Half-Life and Enhances Its Antitumor Activity
    Article Snippet: .. However, for therapy using recombinant human TRAIL (rhTRAIL or Dulanermin, Genentech/Amgen), one major limitation is the rapid blood clearance of TRAIL in vivo. ..



    Similar Products

    recombinant human trail (dulanermin)  (Genentech inc)
    90
    Genentech inc recombinant human trail (dulanermin)
    Recombinant Human Trail (Dulanermin), supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+trail+dulanermin/apo2l+trail/pmc05738353-158-4-8
    Average 90 stars, based on 1 article reviews
    recombinant human trail (dulanermin) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    recombinant human trail dulanermin  (Genentech inc)
    90
    Genentech inc recombinant human trail dulanermin
    (A) Immunoblot analysis <t>of</t> <t>DR5</t> in MCF7 cells treated with 50 μM Celecoxib (CCB), 1 μM Etoposide (E), 100 ng/ml <t>TRAIL</t> (T) and 5 μM withaferin A (WFA) for 6h. (B) MCF7 cells were treated with CCB, Etoposide, TRAIL alone as in A or in combination with 5 μM withaferin A (WFA) for 6h. Cell lysates were immunoblotted for DR5 expression. (C) Breast cancer cells were treated as in B, and subjected to clonogenicity assay. (D) Breast cancer cells were treated as in B, and subjected to soft-agar colony-formation assay for three weeks. Results are expressed as average number of colonies counted (in six micro-fields). *, P<0.001, compared with untreated controls; #, P<0.001, compared with E treated cells; **, P<0.005, compared with CCB treated cells; ***, P<0.001, compared with T treated cells. Vehicle-treated cells are denoted with the letter “C”. (E) Immunoblot analysis of DR5 in stable pools of DR5-depleted (DR5 shRNA1–3) and vector control (pLKO.1) MCF7 and MDA-MB-231 cells. (F) Immunoblot analysis of cleaved PARP and total PARP in MCF7-DR5shRNA1, MCF7-pLKO.1, MDA-MB-231-DR5shRNA1 and MDA-MB-231-pLKO.1 cells treated with 5μM WFA. (G) Clonogenicity of MDA-MB-231-DR5shRNA1, MDA-MB-231-pLKO.1, MCF7-DR5shRNA1,3, and MCF7-pLKO.1 cells in the presence of WFA (5μM). (H, I) Soft-agar colony formation in MDA-MB-231-DR5shRNA1, MDA-MB-231-pLKO.1, MCF7-DR5shRNA1,3 and MCF7-pLKO.1 cells in the presence of WFA (5μM). Results are expressed as average number of colonies counted (in six micro-fields). *, P< 0.001, compared with untreated pLKO.1 cells; #, P< 0.005, compared with untreated DR5shRNA cells. (J, K, L) MDA-MB-231-pLKO.1, MDA-MB-231-DR5shRNA1 and MDA-MB-231-DR5shRNA2 cells derived tumors were developed in nude mice and treated with vehicle or WFA. Tumor growth was monitored by measuring the tumor volume for 5 weeks. (n = 8 mice per group); (P< 0.001). Representative tumor images are shown here. Tumor weight is shown in the table.
    Recombinant Human Trail Dulanermin, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+trail+dulanermin/recombinant+human+trail+dulanermin/pmc04009451-442-31-34
    Average 90 stars, based on 1 article reviews
    recombinant human trail dulanermin - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    recombinant human apo2l/trail dulanermin  (Genentech inc)
    90
    Genentech inc recombinant human apo2l/trail dulanermin
    (A) Immunoblot analysis <t>of</t> <t>DR5</t> in MCF7 cells treated with 50 μM Celecoxib (CCB), 1 μM Etoposide (E), 100 ng/ml <t>TRAIL</t> (T) and 5 μM withaferin A (WFA) for 6h. (B) MCF7 cells were treated with CCB, Etoposide, TRAIL alone as in A or in combination with 5 μM withaferin A (WFA) for 6h. Cell lysates were immunoblotted for DR5 expression. (C) Breast cancer cells were treated as in B, and subjected to clonogenicity assay. (D) Breast cancer cells were treated as in B, and subjected to soft-agar colony-formation assay for three weeks. Results are expressed as average number of colonies counted (in six micro-fields). *, P<0.001, compared with untreated controls; #, P<0.001, compared with E treated cells; **, P<0.005, compared with CCB treated cells; ***, P<0.001, compared with T treated cells. Vehicle-treated cells are denoted with the letter “C”. (E) Immunoblot analysis of DR5 in stable pools of DR5-depleted (DR5 shRNA1–3) and vector control (pLKO.1) MCF7 and MDA-MB-231 cells. (F) Immunoblot analysis of cleaved PARP and total PARP in MCF7-DR5shRNA1, MCF7-pLKO.1, MDA-MB-231-DR5shRNA1 and MDA-MB-231-pLKO.1 cells treated with 5μM WFA. (G) Clonogenicity of MDA-MB-231-DR5shRNA1, MDA-MB-231-pLKO.1, MCF7-DR5shRNA1,3, and MCF7-pLKO.1 cells in the presence of WFA (5μM). (H, I) Soft-agar colony formation in MDA-MB-231-DR5shRNA1, MDA-MB-231-pLKO.1, MCF7-DR5shRNA1,3 and MCF7-pLKO.1 cells in the presence of WFA (5μM). Results are expressed as average number of colonies counted (in six micro-fields). *, P< 0.001, compared with untreated pLKO.1 cells; #, P< 0.005, compared with untreated DR5shRNA cells. (J, K, L) MDA-MB-231-pLKO.1, MDA-MB-231-DR5shRNA1 and MDA-MB-231-DR5shRNA2 cells derived tumors were developed in nude mice and treated with vehicle or WFA. Tumor growth was monitored by measuring the tumor volume for 5 weeks. (n = 8 mice per group); (P< 0.001). Representative tumor images are shown here. Tumor weight is shown in the table.
    Recombinant Human Apo2l/Trail Dulanermin, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+trail+dulanermin/apo2l+trail/10__1097_slash_01__jto__0000438438__14562__c8-26462-13-16
    Average 90 stars, based on 1 article reviews
    recombinant human apo2l/trail dulanermin - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    recombinant human apo2l/trail (dulanermin  (Genentech inc)
    90
    Genentech inc recombinant human apo2l/trail (dulanermin
    (A) Immunoblot analysis <t>of</t> <t>DR5</t> in MCF7 cells treated with 50 μM Celecoxib (CCB), 1 μM Etoposide (E), 100 ng/ml <t>TRAIL</t> (T) and 5 μM withaferin A (WFA) for 6h. (B) MCF7 cells were treated with CCB, Etoposide, TRAIL alone as in A or in combination with 5 μM withaferin A (WFA) for 6h. Cell lysates were immunoblotted for DR5 expression. (C) Breast cancer cells were treated as in B, and subjected to clonogenicity assay. (D) Breast cancer cells were treated as in B, and subjected to soft-agar colony-formation assay for three weeks. Results are expressed as average number of colonies counted (in six micro-fields). *, P<0.001, compared with untreated controls; #, P<0.001, compared with E treated cells; **, P<0.005, compared with CCB treated cells; ***, P<0.001, compared with T treated cells. Vehicle-treated cells are denoted with the letter “C”. (E) Immunoblot analysis of DR5 in stable pools of DR5-depleted (DR5 shRNA1–3) and vector control (pLKO.1) MCF7 and MDA-MB-231 cells. (F) Immunoblot analysis of cleaved PARP and total PARP in MCF7-DR5shRNA1, MCF7-pLKO.1, MDA-MB-231-DR5shRNA1 and MDA-MB-231-pLKO.1 cells treated with 5μM WFA. (G) Clonogenicity of MDA-MB-231-DR5shRNA1, MDA-MB-231-pLKO.1, MCF7-DR5shRNA1,3, and MCF7-pLKO.1 cells in the presence of WFA (5μM). (H, I) Soft-agar colony formation in MDA-MB-231-DR5shRNA1, MDA-MB-231-pLKO.1, MCF7-DR5shRNA1,3 and MCF7-pLKO.1 cells in the presence of WFA (5μM). Results are expressed as average number of colonies counted (in six micro-fields). *, P< 0.001, compared with untreated pLKO.1 cells; #, P< 0.005, compared with untreated DR5shRNA cells. (J, K, L) MDA-MB-231-pLKO.1, MDA-MB-231-DR5shRNA1 and MDA-MB-231-DR5shRNA2 cells derived tumors were developed in nude mice and treated with vehicle or WFA. Tumor growth was monitored by measuring the tumor volume for 5 weeks. (n = 8 mice per group); (P< 0.001). Representative tumor images are shown here. Tumor weight is shown in the table.
    Recombinant Human Apo2l/Trail (Dulanermin, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+trail+dulanermin/apo2l+trail/pmc03012138-249-32-36
    Average 90 stars, based on 1 article reviews
    recombinant human apo2l/trail (dulanermin - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    dulanermin recombinant human apo2l/trail  (Amgen)
    90
    Amgen dulanermin recombinant human apo2l/trail
    (A) Immunoblot analysis <t>of</t> <t>DR5</t> in MCF7 cells treated with 50 μM Celecoxib (CCB), 1 μM Etoposide (E), 100 ng/ml <t>TRAIL</t> (T) and 5 μM withaferin A (WFA) for 6h. (B) MCF7 cells were treated with CCB, Etoposide, TRAIL alone as in A or in combination with 5 μM withaferin A (WFA) for 6h. Cell lysates were immunoblotted for DR5 expression. (C) Breast cancer cells were treated as in B, and subjected to clonogenicity assay. (D) Breast cancer cells were treated as in B, and subjected to soft-agar colony-formation assay for three weeks. Results are expressed as average number of colonies counted (in six micro-fields). *, P<0.001, compared with untreated controls; #, P<0.001, compared with E treated cells; **, P<0.005, compared with CCB treated cells; ***, P<0.001, compared with T treated cells. Vehicle-treated cells are denoted with the letter “C”. (E) Immunoblot analysis of DR5 in stable pools of DR5-depleted (DR5 shRNA1–3) and vector control (pLKO.1) MCF7 and MDA-MB-231 cells. (F) Immunoblot analysis of cleaved PARP and total PARP in MCF7-DR5shRNA1, MCF7-pLKO.1, MDA-MB-231-DR5shRNA1 and MDA-MB-231-pLKO.1 cells treated with 5μM WFA. (G) Clonogenicity of MDA-MB-231-DR5shRNA1, MDA-MB-231-pLKO.1, MCF7-DR5shRNA1,3, and MCF7-pLKO.1 cells in the presence of WFA (5μM). (H, I) Soft-agar colony formation in MDA-MB-231-DR5shRNA1, MDA-MB-231-pLKO.1, MCF7-DR5shRNA1,3 and MCF7-pLKO.1 cells in the presence of WFA (5μM). Results are expressed as average number of colonies counted (in six micro-fields). *, P< 0.001, compared with untreated pLKO.1 cells; #, P< 0.005, compared with untreated DR5shRNA cells. (J, K, L) MDA-MB-231-pLKO.1, MDA-MB-231-DR5shRNA1 and MDA-MB-231-DR5shRNA2 cells derived tumors were developed in nude mice and treated with vehicle or WFA. Tumor growth was monitored by measuring the tumor volume for 5 weeks. (n = 8 mice per group); (P< 0.001). Representative tumor images are shown here. Tumor weight is shown in the table.
    Dulanermin Recombinant Human Apo2l/Trail, supplied by Amgen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+trail+dulanermin/rhapo2l+trail/10__1038_slash_scibx__2009__1098-66-0-21
    Average 90 stars, based on 1 article reviews
    dulanermin recombinant human apo2l/trail - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Immunoblot analysis of DR5 in MCF7 cells treated with 50 μM Celecoxib (CCB), 1 μM Etoposide (E), 100 ng/ml TRAIL (T) and 5 μM withaferin A (WFA) for 6h. (B) MCF7 cells were treated with CCB, Etoposide, TRAIL alone as in A or in combination with 5 μM withaferin A (WFA) for 6h. Cell lysates were immunoblotted for DR5 expression. (C) Breast cancer cells were treated as in B, and subjected to clonogenicity assay. (D) Breast cancer cells were treated as in B, and subjected to soft-agar colony-formation assay for three weeks. Results are expressed as average number of colonies counted (in six micro-fields). *, P<0.001, compared with untreated controls; #, P<0.001, compared with E treated cells; **, P<0.005, compared with CCB treated cells; ***, P<0.001, compared with T treated cells. Vehicle-treated cells are denoted with the letter “C”. (E) Immunoblot analysis of DR5 in stable pools of DR5-depleted (DR5 shRNA1–3) and vector control (pLKO.1) MCF7 and MDA-MB-231 cells. (F) Immunoblot analysis of cleaved PARP and total PARP in MCF7-DR5shRNA1, MCF7-pLKO.1, MDA-MB-231-DR5shRNA1 and MDA-MB-231-pLKO.1 cells treated with 5μM WFA. (G) Clonogenicity of MDA-MB-231-DR5shRNA1, MDA-MB-231-pLKO.1, MCF7-DR5shRNA1,3, and MCF7-pLKO.1 cells in the presence of WFA (5μM). (H, I) Soft-agar colony formation in MDA-MB-231-DR5shRNA1, MDA-MB-231-pLKO.1, MCF7-DR5shRNA1,3 and MCF7-pLKO.1 cells in the presence of WFA (5μM). Results are expressed as average number of colonies counted (in six micro-fields). *, P< 0.001, compared with untreated pLKO.1 cells; #, P< 0.005, compared with untreated DR5shRNA cells. (J, K, L) MDA-MB-231-pLKO.1, MDA-MB-231-DR5shRNA1 and MDA-MB-231-DR5shRNA2 cells derived tumors were developed in nude mice and treated with vehicle or WFA. Tumor growth was monitored by measuring the tumor volume for 5 weeks. (n = 8 mice per group); (P< 0.001). Representative tumor images are shown here. Tumor weight is shown in the table.

    Journal: Cancer research

    Article Title: Mechanistic elucidation of the antitumor properties of withaferin A in breast cancer

    doi: 10.1158/0008-5472.CAN-13-2081

    Figure Lengend Snippet: (A) Immunoblot analysis of DR5 in MCF7 cells treated with 50 μM Celecoxib (CCB), 1 μM Etoposide (E), 100 ng/ml TRAIL (T) and 5 μM withaferin A (WFA) for 6h. (B) MCF7 cells were treated with CCB, Etoposide, TRAIL alone as in A or in combination with 5 μM withaferin A (WFA) for 6h. Cell lysates were immunoblotted for DR5 expression. (C) Breast cancer cells were treated as in B, and subjected to clonogenicity assay. (D) Breast cancer cells were treated as in B, and subjected to soft-agar colony-formation assay for three weeks. Results are expressed as average number of colonies counted (in six micro-fields). *, P<0.001, compared with untreated controls; #, P<0.001, compared with E treated cells; **, P<0.005, compared with CCB treated cells; ***, P<0.001, compared with T treated cells. Vehicle-treated cells are denoted with the letter “C”. (E) Immunoblot analysis of DR5 in stable pools of DR5-depleted (DR5 shRNA1–3) and vector control (pLKO.1) MCF7 and MDA-MB-231 cells. (F) Immunoblot analysis of cleaved PARP and total PARP in MCF7-DR5shRNA1, MCF7-pLKO.1, MDA-MB-231-DR5shRNA1 and MDA-MB-231-pLKO.1 cells treated with 5μM WFA. (G) Clonogenicity of MDA-MB-231-DR5shRNA1, MDA-MB-231-pLKO.1, MCF7-DR5shRNA1,3, and MCF7-pLKO.1 cells in the presence of WFA (5μM). (H, I) Soft-agar colony formation in MDA-MB-231-DR5shRNA1, MDA-MB-231-pLKO.1, MCF7-DR5shRNA1,3 and MCF7-pLKO.1 cells in the presence of WFA (5μM). Results are expressed as average number of colonies counted (in six micro-fields). *, P< 0.001, compared with untreated pLKO.1 cells; #, P< 0.005, compared with untreated DR5shRNA cells. (J, K, L) MDA-MB-231-pLKO.1, MDA-MB-231-DR5shRNA1 and MDA-MB-231-DR5shRNA2 cells derived tumors were developed in nude mice and treated with vehicle or WFA. Tumor growth was monitored by measuring the tumor volume for 5 weeks. (n = 8 mice per group); (P< 0.001). Representative tumor images are shown here. Tumor weight is shown in the table.

    Article Snippet: It is interesting to note that in recent years, many phase 1 and 2 single agent and combination clinical trials have been conducted to examine the efficacy and safety of recombinant human TRAIL (dulanermin, (Amgen/Genentech)), and the agonistic monoclonal antibodies to DR5 (lexatumumab (Human Genome Sciences), conatumumab (Amgen), drozitumab (Genentech), tigatuzumab (Daiichi-Sankyo) and LBY135 (Novartis)) ( 44 , 47 ).

    Techniques: Western Blot, Expressing, Soft Agar Assay, Plasmid Preparation, Control, Derivative Assay